A James M Daveson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5287676/publications.pdf

Version: 2024-02-01

20 papers	850 citations	759233 12 h-index	839539 18 g-index
20 all docs	20 docs citations	20 times ranked	924 citing authors

#	Article	IF	Citations
1	Effect of Hookworm Infection on Wheat Challenge in Celiac Disease â€“ A Randomised Double-Blinded Placebo Controlled Trial. PLoS ONE, 2011, 6, e17366.	2.5	188
2	Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. The Lancet Gastroenterology and Hepatology, 2017, 2, 479-493.	8.1	113
3	Characterising the Mucosal and Systemic Immune Responses to Experimental Human Hookworm Infection. PLoS Pathogens, 2012, 8, e1002520.	4.7	110
4	Suppression of Inflammatory Immune Responses in Celiac Disease by Experimental Hookworm Infection. PLoS ONE, 2011, 6, e24092.	2.5	105
5	Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. EBioMedicine, 2017, 26, 78-90.	6.1	51
6	Elevated serum interleukinâ€2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 901-910.	3.7	51
7	Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on glutenâ€free diet. GastroHep, 2020, 2, 22-30.	0.6	43
8	Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an <scp>A</scp>ustralasian perspective. Internal Medicine Journal, 2015, 45, 441-450.	0.8	40
9	Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clinical and Experimental Immunology, 2019, 199, 68-78.	2.6	36
10	Randomised clinical trial: a placeboâ€controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 547-555.	3.7	35
11	Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 244-252.	3.7	27
12	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Medicine, 2020, 18, 362.	5.5	22
13	A case of an isolated gastric variceal bleed secondary to a pancreatic neuroendocrine tumour. European Journal of Gastroenterology and Hepatology, 2007, 19, 1144-1148.	1.6	10
14	Small bowel endoscopy and coeliac disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 315-323.	2.4	8
15	Inflammatory Bowel Disease Clinical. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 127-155.	2.8	4
16	Future Perspectives of Small Bowel Capsule Endoscopy. , 2008, , 262-270.		3
17	846 Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2Â®, a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD). Gastroenterology, 2016, 150, S180.	1.3	2
18	Discrepancies in genetic testing results for coeliac disease: call for standardised testing and reporting. Medical Journal of Australia, 2017, 207, 179-180.	1.7	1

#	Article	IF	Citations
19	Editorial: inaccuracies in attribution of symptoms due to glutenâ€"not just in those with selfâ€reported noncoeliac gluten sensitivity. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 403-404.	3.7	1
20	A case of periportal fibrosis in a Sudanese refugee. Medical Journal of Australia, 2008, 188, 677-678.	1.7	0